Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 2Lymphoid 2

Conditions

Myelodysplastic Syndromes 355Leukemia, Myeloid, Acute 297Myeloproliferative Disorders 155Leukemia, Myelogenous, Chronic, BCR-ABL Positive 139Precursor Cell Lymphoblastic Leukemia-Lymphoma 115Primary Myelofibrosis 101Leukemia, Myelomonocytic, Chronic 88Lymphoma, Non-Hodgkin 76Leukemia 69Polycythemia Vera 61Multiple Myeloma 55Hodgkin Disease 50Hematologic Neoplasms 48Leukemia, Lymphocytic, Chronic, B-Cell 43Lymphoma 40Leukemia, Biphenotypic, Acute 40Thrombocythemia, Essential 39Myelodysplastic-Myeloproliferative Diseases 31Neoplasms 29Leukemia, Myeloid, Chronic-Phase 28Anemia, Refractory, with Excess of Blasts 24Recurrence 22Anemia, Aplastic 21Lymphoma, Mantle-Cell 20Lymphoma, Follicular 20Hematologic Diseases 20Burkitt Lymphoma 20Blastic Plasmacytoid Dendritic Cell Neoplasm 20Blast Crisis 20Histiocytosis, Langerhans-Cell 18

Interventions

nilotinib 2asciminib 2bosutinib 1Imatinib Mesylate 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Philadelphia Chromosome × Myeloid × 1 year × Clear all
NCT04971226 2026-06-05

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Novartis

Phase 3 Active not recruiting
405 enrolled 18 charts 1 FDA
MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05456191 2026-05-27

ASC4START

Novartis

Phase 3 Active not recruiting
568 enrolled 11 charts
MyeloidOther hematologic neoplasm

Leukemia, Myeloproliferative Disorders, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡